NASDAQ:KTOV - Kitov Pharma Stock Price, Price Target & More

$2.47 -0.08 (-3.14 %)
(As of 04/24/2018 02:59 AM ET)
Previous Close$2.47
Today's Range$2.45 - $2.59
52-Week Range$1.27 - $3.44
Volume72,177 shs
Average Volume116,417 shs
Market Capitalization$28.58 million
P/E Ratio-1.90
Dividend YieldN/A
Beta2.82

About Kitov Pharma (NASDAQ:KTOV)

Kitov Pharma logoKitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study. It is also developing NT219, a small molecule that targets two pathways involved in cancer drug resistance. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. Kitov Pharma Ltd was founded in 2010 and is headquartered in Tel Aviv, Israel.

Receive KTOV News and Ratings via Email

Sign-up to receive the latest news and ratings for KTOV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KTOV
CUSIPN/A
Phone972-3933-3121

Debt

Debt-to-Equity RatioN/A
Current Ratio1.97%
Quick Ratio1.97%

Price-To-Earnings

Trailing P/E Ratio-1.90
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.77 per share
Price / Book3.21

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees9
Outstanding Shares11,210,000

How to Become a New Pot Stock Millionaire

Kitov Pharma (NASDAQ:KTOV) Frequently Asked Questions

What is Kitov Pharma's stock symbol?

Kitov Pharma trades on the NASDAQ under the ticker symbol "KTOV."

When is Kitov Pharma's next earnings date?

Kitov Pharma is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Kitov Pharma.

What price target have analysts set for KTOV?

1 equities research analysts have issued 1 year price objectives for Kitov Pharma's shares. Their predictions range from $10.00 to $10.00. On average, they expect Kitov Pharma's stock price to reach $10.00 in the next year. View Analyst Ratings for Kitov Pharma.

Who are some of Kitov Pharma's key competitors?

Who are Kitov Pharma's key executives?

Kitov Pharma's management team includes the folowing people:
  • Dr. John Paul Waymack M.D., Sc.D., Founder, Chairman & Chief Medical Officer (Age 66)
  • Mr. Isaac Israel, CEO & Director (Age 40)
  • Dr. Hadas Reuveni, Founder & Chief Technology Officer, TyrNovo (Age 51)
  • Mr. Simcha Rock CPA, MBA, CFO & Director (Age 68)
  • Dr. Gil Ben-Menachem MSc, MBA, Ph.D., VP of Bus. Devel. & Director (Age 51)

When did Kitov Pharma IPO?

(KTOV) raised $13 million in an IPO on Friday, November 20th 2015. The company issued 3,200,000 shares at $4.13 per share. Rodman & Renshaw (a unit of H.C. Wainwright & Co.,) and Joseph Gunnar served as the underwriters for the IPO.

Has Kitov Pharma been receiving favorable news coverage?

Press coverage about KTOV stock has been trending positive recently, Accern reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kitov Pharma earned a media sentiment score of 0.31 on Accern's scale. They also assigned news coverage about the company an impact score of 45.68 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Kitov Pharma?

Shares of KTOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kitov Pharma's stock price today?

One share of KTOV stock can currently be purchased for approximately $2.47.

How big of a company is Kitov Pharma?

Kitov Pharma has a market capitalization of $28.58 million. The company earns $-12,270,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. Kitov Pharma employs 9 workers across the globe.

How can I contact Kitov Pharma?

Kitov Pharma's mailing address is One Azrieli Center 132 Menachem Begin Road, Tel Aviv L3, 6701101. The company can be reached via phone at 972-3933-3121.


MarketBeat Community Rating for Kitov Pharma (KTOV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  53 (Vote Underperform)
Total Votes:  130
MarketBeat's community ratings are surveys of what our community members think about Kitov Pharma and other stocks. Vote "Outperform" if you believe KTOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KTOV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kitov Pharma (NASDAQ:KTOV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Kitov Pharma in the last 12 months. Their average twelve-month price target is $10.00, suggesting that the stock has a possible upside of 304.86%. The high price target for KTOV is $10.00 and the low price target for KTOV is $10.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.00$10.00$10.00N/A
Price Target Upside: 304.86% upside407.61% upside407.61% upsideN/A

Kitov Pharma (NASDAQ:KTOV) Consensus Price Target History

Price Target History for Kitov Pharma (NASDAQ:KTOV)

Kitov Pharma (NASDAQ:KTOV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017HC WainwrightUpgradeNeutral -> Buy$10.00N/AView Rating Details
7/11/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Dividends

Kitov Pharma (NASDAQ:KTOV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Kitov Pharma (NASDAQ KTOV) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.70%
Insider Trading History for Kitov Pharma (NASDAQ:KTOV)
Institutional Ownership by Quarter for Kitov Pharma (NASDAQ:KTOV)

Kitov Pharma (NASDAQ KTOV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Kitov Pharma (NASDAQ KTOV) News Headlines

Source:
DateHeadline
Zacks: Analysts Anticipate Kitov Pharma (KTOV) Will Post Earnings of -$0.01 Per ShareZacks: Analysts Anticipate Kitov Pharma (KTOV) Will Post Earnings of -$0.01 Per Share
www.americanbankingnews.com - April 23 at 11:10 PM
 Kitov Pharma (KTOV) Given $10.00 Consensus Price Target by Brokerages Kitov Pharma (KTOV) Given $10.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - April 17 at 3:23 PM
TyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer ResearchTyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer Research
finance.yahoo.com - April 13 at 10:10 AM
-$0.01 EPS Expected for Kitov Pharma (KTOV) This Quarter-$0.01 EPS Expected for Kitov Pharma (KTOV) This Quarter
www.americanbankingnews.com - April 6 at 11:20 PM
 Kitov Pharma Ltd (KTOV) Given $10.00 Consensus Target Price by Brokerages Kitov Pharma Ltd (KTOV) Given $10.00 Consensus Target Price by Brokerages
www.americanbankingnews.com - April 1 at 3:10 AM
Zacks: Analysts Anticipate Kitov Pharma Ltd (KTOV) Will Post Earnings of -$0.01 Per ShareZacks: Analysts Anticipate Kitov Pharma Ltd (KTOV) Will Post Earnings of -$0.01 Per Share
www.americanbankingnews.com - March 21 at 1:28 AM
Brokerages Anticipate Kitov Pharma Ltd (KTOV) to Post ($0.01) Earnings Per ShareBrokerages Anticipate Kitov Pharma Ltd (KTOV) to Post ($0.01) Earnings Per Share
www.americanbankingnews.com - March 17 at 3:06 AM
Kitov Pharmaceuticals Publishes Annual Report for 2017 and Issues CEO Letter to ShareholdersKitov Pharmaceuticals Publishes Annual Report for 2017 and Issues CEO Letter to Shareholders
finance.yahoo.com - March 5 at 10:01 AM
ValuEngine Lowers Kitov Pharma (KTOV) to SellValuEngine Lowers Kitov Pharma (KTOV) to Sell
www.americanbankingnews.com - March 4 at 3:25 PM
Analysts Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) to Post ($0.01) Earnings Per ShareAnalysts Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) to Post ($0.01) Earnings Per Share
www.americanbankingnews.com - February 19 at 1:16 AM
 Brokerages Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) Will Announce Earnings of -$0.01 Per Share Brokerages Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) Will Announce Earnings of -$0.01 Per Share
www.americanbankingnews.com - February 15 at 3:16 AM
Zacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Given Average Rating of "Strong Buy" by BrokeragesZacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 30 at 1:20 PM
Zacks: Brokerages Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) to Announce -$0.01 EPSZacks: Brokerages Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) to Announce -$0.01 EPS
www.americanbankingnews.com - January 29 at 5:12 AM
Zacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Receives Average Recommendation of "Strong Buy" from BrokeragesZacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - January 22 at 5:18 AM
-$0.01 EPS Expected for Kitov Pharmaceuticals Holdings Ltd (KTOV) This Quarter-$0.01 EPS Expected for Kitov Pharmaceuticals Holdings Ltd (KTOV) This Quarter
www.americanbankingnews.com - January 12 at 8:02 AM
Zacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Given Consensus Rating of "Strong Buy" by BrokeragesZacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 5 at 7:12 PM
Zacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Given $10.00 Average Target Price by BrokeragesZacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Given $10.00 Average Target Price by Brokerages
www.americanbankingnews.com - December 16 at 9:56 AM
Kitov Announces Consensi™ as Brand Name for KIT-302Kitov Announces Consensi™ as Brand Name for KIT-302
finance.yahoo.com - December 14 at 6:06 PM
Kitov Pharmaceuticals (KTOV) & Edge Therapeutics (EDGE) Head-To-Head SurveyKitov Pharmaceuticals (KTOV) & Edge Therapeutics (EDGE) Head-To-Head Survey
www.americanbankingnews.com - December 12 at 7:57 AM
 Analysts Set $10.00 Target Price for Kitov Pharmaceuticals Holdings Ltd. (KTOV) Analysts Set $10.00 Target Price for Kitov Pharmaceuticals Holdings Ltd. (KTOV)
www.americanbankingnews.com - November 25 at 3:24 AM
Kitov Pharmaceuticals Holdings Ltd. (KTOV) Stock Rating Upgraded by HC WainwrightKitov Pharmaceuticals Holdings Ltd. (KTOV) Stock Rating Upgraded by HC Wainwright
www.americanbankingnews.com - November 21 at 4:41 PM
Kitov Pharmaceuticals Holdings (KTOV) versus Aurinia Pharmaceuticals (AUPH) Head to Head ReviewKitov Pharmaceuticals Holdings (KTOV) versus Aurinia Pharmaceuticals (AUPH) Head to Head Review
www.americanbankingnews.com - November 6 at 1:33 PM
BRIEF-Kitov pharmaceuticals announces receipt of FDAs favorable response to NT219s pre-ind meeting packageBRIEF-Kitov pharmaceuticals announces receipt of FDA's favorable response to NT219's pre-ind meeting package
www.reuters.com - November 3 at 6:50 PM
Kitov Pharmaceuticals Announces Receipt of FDAs Favorable Response to NT219s pre-IND Meeting PackageKitov Pharmaceuticals Announces Receipt of FDA's Favorable Response to NT219's pre-IND Meeting Package
finance.yahoo.com - November 2 at 4:47 AM
Kitov Pharmaceuticals: An UpdateKitov Pharmaceuticals: An Update
seekingalpha.com - November 1 at 5:06 AM
Kitov Pharmaceuticals Announces Phase III/IV Clinical Trial for KIT-302 Successfully Meets Primary Endpoint, and also Demonstrates Drug Candidate Improves Renal FunctionKitov Pharmaceuticals Announces Phase III/IV Clinical Trial for KIT-302 Successfully Meets Primary Endpoint, and also Demonstrates Drug Candidate Improves Renal Function
finance.yahoo.com - October 26 at 4:48 PM
BRIEF-Kitov boosts ownership in Tyrnovo and Oncology platformBRIEF-Kitov boosts ownership in Tyrnovo and Oncology platform
www.reuters.com - October 7 at 2:08 AM
Kitov ups stake in oncology-focused TyrNovo to 92%; shares ahead 9% premarketKitov ups stake in oncology-focused TyrNovo to 92%; shares ahead 9% premarket
seekingalpha.com - October 7 at 2:08 AM
Kitov Boosts Ownership in TyrNovo and Oncology Platform Through Exchange of Shares for StockKitov Boosts Ownership in TyrNovo and Oncology Platform Through Exchange of Shares for Stock
finance.yahoo.com - October 7 at 2:08 AM
Pro-Trader Daily: Corporate News Blog - US FDA Accepts Kitov Pharmas Lead Drug Candidate for Full ReviewPro-Trader Daily: Corporate News Blog - US FDA Accepts Kitov Pharma's Lead Drug Candidate for Full Review
www.finanznachrichten.de - October 5 at 7:37 AM
Corporate News Blog - US FDA Accepts Kitov Pharma’s Lead Drug Candidate for Full ReviewCorporate News Blog - US FDA Accepts Kitov Pharma’s Lead Drug Candidate for Full Review
finance.yahoo.com - October 5 at 7:37 AM
Kitov Pharma (KTOV) Reports FDA Filing for New Drug Application for KIT-302Kitov Pharma (KTOV) Reports FDA Filing for New Drug Application for KIT-302
www.streetinsider.com - October 2 at 12:32 PM
Kitov files U.S. marketing application for lead candidate KIT-302; shares ahead 8% premarketKitov files U.S. marketing application for lead candidate KIT-302; shares ahead 8% premarket
seekingalpha.com - October 2 at 12:32 PM
Kitov Announces Filing by FDA of New Drug Application for KIT-302Kitov Announces Filing by FDA of New Drug Application for KIT-302
finance.yahoo.com - October 2 at 12:32 PM
Kitov Pharmaceuticals Holdings Ltd. (KTOV) Expected to Announce Earnings of -$0.16 Per ShareKitov Pharmaceuticals Holdings Ltd. (KTOV) Expected to Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - August 17 at 6:16 PM
Kitov Pharmaceuticals Provides Corporate Update and Reports First Half 2017 Financial ResultsKitov Pharmaceuticals Provides Corporate Update and Reports First Half 2017 Financial Results
finance.yahoo.com - August 16 at 8:30 PM
Kitov submits U.S. marketing application for lead candidate KIT-302; shares down 3%Kitov submits U.S. marketing application for lead candidate KIT-302; shares down 3%
seekingalpha.com - August 1 at 12:44 AM
Kitov Submits New Drug Application to FDA for KIT-302Kitov Submits New Drug Application to FDA for KIT-302
finance.yahoo.com - July 31 at 7:42 PM
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ:KTOV) Expected to Announce Earnings of -$0.16 Per ShareKitov Pharmaceuticals Holdings Ltd. (NASDAQ:KTOV) Expected to Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - July 30 at 2:09 PM
Kitov Pharma (KTOV) Announces Results Showing NT-219 Enhanced Efficacy of Keytruda in Immune-Oncology Preclinical ModelKitov Pharma (KTOV) Announces Results Showing NT-219 Enhanced Efficacy of Keytruda in Immune-Oncology Preclinical Model
www.streetinsider.com - July 18 at 9:32 PM
Kitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda® in Immune-Oncology Preclinical ModelKitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda® in Immune-Oncology Preclinical Model
finance.yahoo.com - July 18 at 4:29 PM
Kitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct OfferingKitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct Offering
finance.yahoo.com - July 12 at 2:04 AM
Kitov Pharmaceuticals Says on July 6 Named Gil Ben-Menachem to Fill Vacancy on BoardKitov Pharmaceuticals Says on July 6 Named Gil Ben-Menachem to Fill Vacancy on Board
finance.yahoo.com - July 8 at 12:10 PM
Kitov Pharmaceuticals Holdings (KTOV) Has Surged To A 4-Month HighKitov Pharmaceuticals Holdings (KTOV) Has Surged To A 4-Month High
www.rttnews.com - July 7 at 6:54 AM
-$0.16 EPS Expected for Kitov Pharmaceuticals Holdings Ltd. (KTOV) This Quarter-$0.16 EPS Expected for Kitov Pharmaceuticals Holdings Ltd. (KTOV) This Quarter
www.americanbankingnews.com - July 6 at 10:30 AM
Kitov Pharma (KTOV) Provides Update on KIT-302 New Drug ApplicationKitov Pharma (KTOV) Provides Update on KIT-302 New Drug Application
www.streetinsider.com - June 27 at 1:07 AM
BRIEF-Kitov Pharmaceuticals discloses additional details of Israeli Securities Authority investigationBRIEF-Kitov Pharmaceuticals discloses additional details of Israeli Securities Authority investigation
www.reuters.com - May 1 at 5:17 PM
U.S. Food and Drug Administration Grants Kitov a Waiver for New Drug Application Filing FeeU.S. Food and Drug Administration Grants Kitov a Waiver for New Drug Application Filing Fee
www.bizjournals.com - April 4 at 6:44 AM
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with  Losses on their Investment in Kitov Pharmaceuticals Holdings Ltd. of  Class Action Lawsuit and Upcoming Deadline – KTOVSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kitov Pharmaceuticals Holdings Ltd. of Class Action Lawsuit and Upcoming Deadline – KTOV
feeds.benzinga.com - March 31 at 8:31 PM
SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals ... - Business Wire (press release)SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals ... - Business Wire (press release)
www.businesswire.com - March 28 at 10:53 AM

SEC Filings

Kitov Pharma (NASDAQ:KTOV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kitov Pharma (NASDAQ:KTOV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kitov Pharma (NASDAQ KTOV) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.